N S Abraham1, D L Castillo, C Hartman. 1. Houston Center for Quality of Care & Utilization Studies, Michael E. DeBakey VA Medical Center and Baylor College of Medicine, Houston, TX 77030, USA. nabraham@bcm.edu
Abstract
BACKGROUND: Upper gastrointestinal events (UGIE), myocardial infarction (MI) and cerebrovascular accident (CVA) are known morbidities among recent NSAID users. AIM: To assess all-cause mortality following UGIE, MI or CVA among recent NSAID users. METHODS: Veterans >65 prescribed an NSAID at any Veterans Affairs (VA) facility were identified using prescription fill data and their records linked to a merged VA-Medicare database. Each person-day was assessed for NSAID, coxib or proton pump inhibitor (PPI) exposure. Incidence density ratios and hazard rates of death were calculated following UGIE, MI and CVA adjusting for demographics, co-morbidity, prescription channeling, geographic location and pharmacological covariates. RESULTS: Among 474 495 patients [97.8% male; 85.3% white; 73.9 years (s.d. 5.6)], death followed at a rate of 5.5 per 1000 person-years (95% CI: 5.4-5.6) post-UGIE, 17.7 per 1000 person-years (95% CI: 17.5-17.9) post-MI and 21.8 per 1000 person-years (95% CI: 21.6-22.0) post-CVA. CVA was associated with greatest risk of death [hazard ratio (HR) 12.4; 95% CI: 10.9-14.3] followed by MI (HR 10.7; 95% CI: 9.2-11.6) and UGIE (HR 3.3; 95% CI: 2.8-3.9). Predictors of mortality were advancing age and co-morbidity, increased use of coxibs and failure to ensure adequate gastroprotection. CONCLUSION: Among elderly veterans with recent NSAID use, an UGIE, MI or CVA is a clinically relevant premorbid event.
BACKGROUND: Upper gastrointestinal events (UGIE), myocardial infarction (MI) and cerebrovascular accident (CVA) are known morbidities among recent NSAID users. AIM: To assess all-cause mortality following UGIE, MI or CVA among recent NSAID users. METHODS: Veterans >65 prescribed an NSAID at any Veterans Affairs (VA) facility were identified using prescription fill data and their records linked to a merged VA-Medicare database. Each person-day was assessed for NSAID, coxib or proton pump inhibitor (PPI) exposure. Incidence density ratios and hazard rates of death were calculated following UGIE, MI and CVA adjusting for demographics, co-morbidity, prescription channeling, geographic location and pharmacological covariates. RESULTS: Among 474 495 patients [97.8% male; 85.3% white; 73.9 years (s.d. 5.6)], death followed at a rate of 5.5 per 1000 person-years (95% CI: 5.4-5.6) post-UGIE, 17.7 per 1000 person-years (95% CI: 17.5-17.9) post-MI and 21.8 per 1000 person-years (95% CI: 21.6-22.0) post-CVA. CVA was associated with greatest risk of death [hazard ratio (HR) 12.4; 95% CI: 10.9-14.3] followed by MI (HR 10.7; 95% CI: 9.2-11.6) and UGIE (HR 3.3; 95% CI: 2.8-3.9). Predictors of mortality were advancing age and co-morbidity, increased use of coxibs and failure to ensure adequate gastroprotection. CONCLUSION: Among elderly veterans with recent NSAID use, an UGIE, MI or CVA is a clinically relevant premorbid event.
Authors: Stephen J Kerr; Debra S Rowett; Geoffrey P Sayer; Susan D Whicker; Deborah C Saltman; Andrea Mant Journal: Br J Clin Pharmacol Date: 2010-05-06 Impact factor: 4.335
Authors: V A Dinapoli; S A Benkovic; X Li; K A Kelly; D B Miller; C L Rosen; J D Huber; J P O'Callaghan Journal: Neuroscience Date: 2010-07-13 Impact factor: 3.590